Heart Failure

The AJMC® Heart Failure compendium is a comprehensive resource for clinical news and expert insights for the chronic condition in which the heart doesn't pump enough blood due to damaged heart muscle.

Latest News

Doctor writing prescription | Image credit: 18percentgrey – stock.adobe.com
SGLT2i Prescriptions for Heart Failure Are Rising, but Vary Across US

November 18th 2024

Of the 518 hospitals that had at least 10 eligible discharges, only 11 of them prescribed SGLT2 inhibitors to more than half of their patients.

Liver and stethoscope | Image credit: filins – stock.adobe.com
Liver Fibrosis Scores May Hint at Heart Failure Risk

November 13th 2024

Man having heart attack | Image credit: JU.STOCKER – stock.adobe.com
β-Blockers May Raise Depression Risk for Heart Attack Survivors Without Heart Failure

November 13th 2024

Doctor holding stethoscope to red heart | Image credit: lenets_tan – stock.adobe.com
How the Clinical Trial Gender Gap Affects Women’s Heart Care

October 18th 2024

Woman at heart doctor | Image credit: Seventyfour – stock.adobe.com
Why Are We Still Seeing Gaps in Women’s Heart Care?

October 15th 2024

Heart Failure Clinical and Economic Burden

An in-depth discussion on the clinical and economic burden of treatment for patients with heart failure, with special consideration to progressive disease.

John McMurray screenshot
Continuing Medical Education
View All
November 21st 2024

Advances and Best Practices for Managed Care Pharmacists in the Treatment of Heart Failure with Preserved Ejection Fraction

1.0 Credits / Cardiology
November 21st 2024

Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment

1.5 Credits / Cardiology, Neurology, Rare Diseases
November 21st 2024

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

More News

Site Logo
June 29th 2019

AstraZeneca's Khan Discusses Dapagliflozin and Cardiovascular, Renal Outcomes in Diabetes Care

Mary Caffrey
A discussion with Naeem Khan, MD, vice president of US cardiovascular and metabolic diseases at AstraZeneca, on lessons from the wave of cardiovascular outcomes trials, the new focus on renal outcomes, and what’s next for SGLT2 inhibitors.
FDA's Fast Track Designation for Empagliflozin in Heart Failure Points to New Paradigm
June 28th 2019

FDA's Fast Track Designation for Empagliflozin in Heart Failure Points to New Paradigm

Mary Caffrey
The EMPEROR trials could lead to new indications for the SGLT2 inhibitor for patients with and without diabetes.
This Week in Managed Care: May 10, 2019
May 10th 2019

This Week in Managed Care: May 10, 2019

This week, the top managed care news included HHS announcing a finalized rule requiring the disclosure of drug prices in television ads; a report finding high satisfaction with employer health coverage despite the cost; a study finding heart failure is surging among young adults.
What We're Reading: Medicaid Fraud Settlement; Heart Failure in Young Adults; FDA Investigates Sunscreen
May 7th 2019

What We're Reading: Medicaid Fraud Settlement; Heart Failure in Young Adults; FDA Investigates Sunscreen

AJMC Staff
Federal prosecutors have reached a $17 million settlement with Acadia after Medicaid fraud allegations; rates of heart failure–related deaths are on the rise among adults between 35 and 64 years old; the FDA has asked manufacturers of sunscreen to review the safety of the chemicals used in their products after a new study found that many of the ingredients in sunscreen may be absorbed into the bloodstream upon use.
5 Takeaways From the 2019 American College of Cardiology Meeting
March 22nd 2019

5 Takeaways From the 2019 American College of Cardiology Meeting

Mary Caffrey
For SGLT2 inhibitors and a fish oil capsule, there was plenty of good news; for aspirin, not so much. A recap of the American College of Cardiology's 68th Annual Scientific Session, held March 16-18, 2019, in New Orleans, Louisiana.
Site Logo
March 18th 2019

Relationship Between Heart Failure and Diabetes Seen Throughout ACC Sessions

Mary Caffrey
More than a decade after an FDA mandate for cardiovascular outcomes trials, cardiologists say insights gained on how 2 new drug classes affect heart failure in diabetes should be used to prevent complications. Several sessions at the 68th Scientific Session of the American College of Cardiology addressed this topic.
Site Logo
March 17th 2019

Debate Over 30-Day Readmission Metric Dominates Quality Session

Mary Caffrey
A session at the 68th American College of Cardiology Scientific Session continues the ongoing debate whether a CMS reimbursement model has contributed to rising mortality in patients with heart failure.
Site Logo
March 16th 2019

Giant Study Suggests Apple Watch Accurately Catches Atrial Fibrillation

Mary Caffrey
The 68th American College of Cardiology Scientific Session and Exposition opens with a study that suggests the Apple Watch can detect atrial fibrillation with a reasonable degree of accuracy, giving people an opportunity to get in touch with their doctor before a serious event like a stroke.
From the Apple Watch to Heart Failure at Annual Cardiologists' Meeting
March 16th 2019

From the Apple Watch to Heart Failure at Annual Cardiologists' Meeting

Mary Caffrey
In recent years, the big news on the first day of the American College of Cardiology (ACC) Scientific Session and Exposition has involved a therapy—usually an expensive cholesterol drug with a name almost no one could pronounce: proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. This year, it's tech, and an easy-to-pronounce name: Apple.
Diabetes Updates: Glucose From Siri, New Indication for Soliqua, More Recalls for Valsartan
March 2nd 2019

Diabetes Updates: Glucose From Siri, New Indication for Soliqua, More Recalls for Valsartan

AJMC Staff
A technology update, a new drug approval, and a drug recall due to more impurities.
New Analysis Finds Hope for Reducing Heart Failure
January 12th 2019

New Analysis Finds Hope for Reducing Heart Failure

Mary Caffrey
The analysis discusses the strength of evidence that SGLT2 inhibitors have a class effect in preventing heart failure for patients with diabetes.
People Living With HIV Have 2-Fold Risk of Heart Failure
January 5th 2019

People Living With HIV Have 2-Fold Risk of Heart Failure

Jaime Rosenberg
People living with HIV are at a greater risk for incident heart failure, with those with higher viral loads and lower CD4+ T cell counts having the greatest risk.
COPD Increases Risk of Death in Patients With Heart Failure
December 22nd 2018

COPD Increases Risk of Death in Patients With Heart Failure

Allison Inserro
Increased severity of chronic obstructive pulmonary disease (COPD) was associated with an increased risk of mortality and hospitalization in patients with heart failure, according to a recent study published in JAMA Open.
Cardiovascular Results for Dapagliflozin Point to SGLT2 Use to Prevent Heart Failure
November 11th 2018

Cardiovascular Results for Dapagliflozin Point to SGLT2 Use to Prevent Heart Failure

Mary Caffrey
Results presented at the American Heart Association in Chicago provided the strongest evidence to date on what heart failure specialists have discussed for several years now: the possibility that SGLT2 inhibitors might be used to prevent heart failure in patients with type 2 diabetes.
Site Logo
September 24th 2018

MitraClip Reduces Hospital Stays, Deaths Among Patients With Heart Failure

Mary Caffrey
Heart failure hospitalization has been a target for accountable care organizations seeking to find ways to cut costs from the healthcare system. But it remains to be seen how many of the estimated 2 million patients would gain access to the device if it received an expanded indication and payer coverage.
Site Logo
August 30th 2018

How Michigan Hospitals Utilize Technology to Track and Target Heart Failure Care

Michigan Value Collaborative
Hospital participants shared how they have utilized technology to enhance care for heart failure patients. Below are some highlights of these resources and initiatives.
Collaborative Care Intervention Did Not Improve Health Status of Patients With Heart Failure
July 27th 2018

Collaborative Care Intervention Did Not Improve Health Status of Patients With Heart Failure

Samantha DiGrande
In a recent study, researchers looked to determine whether a symptom and psychosocial collaborative care intervention would improve heart failure–specific health status, depression, and symptom burden in patients with heart failure.
Dr Mary Norine Walsh on Who Is at High Risk for Peripartum Cardiomyopathy
June 21st 2018

Dr Mary Norine Walsh on Who Is at High Risk for Peripartum Cardiomyopathy

Mary Norine Walsh, MD, immediate past president of the American College of Cardiology, discusses the symptoms of peripartum cardiomyopathy, and who is at the highest risk for developing it.
Site Logo
April 23rd 2018

JAMA Comparison: SGLT2 Inhibitors, GLP-1 Agonists Offer Lower Mortality in Type 2 Diabetes

Mary Caffrey
Guidance for primary care physicians prescribing type 2 diabetes therapies comes at an opportune time. A major rift over guidelines for glycemic control has opened between the American College of Physicians, a professional association of internists, and diabetes specialists, including endocrinologists and diabetes educators.
Medicare's Reliance on 3 Conditions to Calculate Quality, Penalties Called "Incomplete" by Study
March 27th 2018

Medicare's Reliance on 3 Conditions to Calculate Quality, Penalties Called "Incomplete" by Study

Allison Inserro
Condition-specific readmissions measures for heart failure, pneumonia, and heart attack may not accurately or fairly reflect hospital quality, according to a study published this week in the Annals of Internal Medicine. The study found significant differences in hospitals' performance when readmissions were assessed for non-Medicare patients and for conditions other than those currently reported, showing that when these additional factors are taken into account, half of the hospitals would be subject to a change in their financial penalty status.
5 Takeaways From the American College of Cardiology Scientific Session
March 16th 2018

5 Takeaways From the American College of Cardiology Scientific Session

Mary Caffrey
Results from the ODYSSEY Outcomes trial for the PCSK9 inhibitor alirocumab were the top news at the meeting.
Site Logo
March 15th 2018

Medicare Hospital Discharges Decline, but Observation Stays Rise, Avalere Finds

Mary Caffrey
The report finds a connection between payment reform and hospital use patterns, but that connection may add to the debate that cardiologists have raised over the effect on patients.
PCORI Reports Latest Findings From 5 of Their Funded Studies
March 15th 2018

PCORI Reports Latest Findings From 5 of Their Funded Studies

Jaime Rosenberg
The Patient-Centered Outcomes Institute shared results of 5 recent publications summarizing results from their awardees. The studies included research on a decision aid for patients with heart failure, 2 different approaches to treating mental illness, and addressing chronic pain.
Site Logo
March 12th 2018

CVD-REAL Results in More Diverse Countries Link SGLT2s to Lower Risk of Death, Heart Attack, Stroke

Mary Caffrey
CVD-REAL, the giant study of real-world evidence comparing sodium glucose co-transporter-2 (SGLT2) inhibitors with other glucose-lowering drugs to treat type 2 diabetes, found a 49% lower risk of all-cause death and a host of other benefits across 6 new, more diverse countries, the study’s lead author told a packed room Sunday at the 67th Scientific Session of the American College of Cardiology in Orlando, Florida.
Site Logo
March 12th 2018

For Patients With Heart Failure, Healthcare Reform Brings Change and Unintended Consequences

Mary Caffrey
Healthcare reform pledged to do better for patients with heart failure, creating the incentives and team-based approaches these fragile patients need. In some cases, this has happened, but there have also been unintended consequences, according to a panel appearing Sunday at the 67th Scientific Session of the American College of Cardiology, being held in Orlando, Florida.
Patients With Breast Cancer or Lymphoma Have Increased Risk of Heart Failure
March 10th 2018

Patients With Breast Cancer or Lymphoma Have Increased Risk of Heart Failure

Kaitlynn Ely
Patients who had breast cancer or lymphoma who were treated more than 3 times are more likely to develop congestive heart failure than those who did not have cancer, according to research being presented at the American College of Cardiology’s 67th Annual Scientific Session.
Modest Improvement in Heart Failure Patients With Collaborative Care Intervention
March 4th 2018

Modest Improvement in Heart Failure Patients With Collaborative Care Intervention

Samantha DiGrande
A recently published study in JAMA Internal Medicine sought to determine whether a symptom and psychosocial collaborative care intervention improves heart failure–specific health status, depression, and symptom burden in patients with heart failure.
Site Logo
March 1st 2018

Several Walks a Week Can Protect Women From Heart Failure After Menopause

Mary Caffrey
A study being presented at the upcoming meeting of the American College of Cardiology found a dose–response relationship between walking and reduced heart failure risk.
Early Look at ACC Navigator Program Shows Inpatient Mortality Drops as Hospitals Take Positive Steps
February 26th 2018

Early Look at ACC Navigator Program Shows Inpatient Mortality Drops as Hospitals Take Positive Steps

Mary Caffrey
In the next phase of the program, researchers will dig into the data they have gathered so far to identify the best practices for reducing 30- and 90-day readmission rates.
Adhering to Heart Failure Treatment Guidelines More Important Than Volume, Study Finds
February 7th 2018

Adhering to Heart Failure Treatment Guidelines More Important Than Volume, Study Finds

Samantha DiGrande
A recent study appearing in the American Heart Association journal Circulation, found that looking at how well hospitals adhere to treatment guidelines for heart failure is more important than comparing patient volumes at hospitals.
<1
...
12131415161718192021>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo